O	0	6	Better
O	7	17	pathologic
O	18	26	complete
O	27	35	response
O	36	39	and
O	40	47	relapse
O	47	48	-
O	48	52	free
O	53	61	survival
O	62	67	after
B-intervention	68	79	carboplatin
I-intervention	80	84	plus
I-intervention	85	95	paclitaxel
O	96	104	compared
O	105	109	with
B-control	110	120	epirubicin
I-control	121	125	plus
I-control	126	136	paclitaxel
O	137	139	as
O	140	151	neoadjuvant
O	152	164	chemotherapy
O	165	168	for
O	169	176	locally
O	177	185	advanced
O	186	192	triple
O	192	193	-
O	193	201	negative
O	202	208	breast
O	209	215	cancer
O	215	216	:
O	217	218	a
O	219	229	randomized
O	230	235	phase
O	236	237	2
O	238	243	trial
O	243	244	.

O	245	247	No
O	248	256	standard
O	257	269	chemotherapy
O	270	272	is
O	273	277	used
O	278	280	as
O	281	292	neoadjuvant
O	293	300	therapy
O	301	303	in
O	304	310	triple
O	311	319	negative
O	320	326	breast
O	327	333	cancer
O	334	335	(
O	335	339	TNBC
O	339	340	)
O	340	341	.

O	342	346	This
O	347	352	study
O	353	356	has
O	357	365	compared
O	366	377	carboplatin
O	378	382	plus
O	383	393	paclitaxel
O	394	398	with
O	399	407	commonly
O	408	412	used
O	413	423	epirubicin
O	424	428	plus
O	429	439	paclitaxel
O	440	442	as
O	443	454	neoadjuvant
O	455	467	chemotherapy
O	468	469	(
O	469	472	NAC
O	472	473	)
O	474	476	in
O	477	481	TNBC
O	481	482	.

B-total-participants	483	485	91
O	486	494	patients
O	495	499	with
O	500	501	a
O	502	508	median
O	509	512	age
O	513	515	of
O	516	518	47
O	519	524	years
O	525	526	(
O	526	528	PC
B-intervention-participants	529	531	47
O	532	540	patients
O	540	541	,
O	542	544	EP
B-control-participants	545	547	44
O	548	556	patients
O	556	557	)
O	558	562	were
O	563	571	enrolled
O	571	572	.

O	573	575	65
O	575	576	%
O	577	579	of
O	580	583	the
O	584	592	patients
O	593	597	were
O	598	611	premenopausal
O	611	612	.

O	613	618	While
O	619	622	the
B-outcome	623	632	objective
I-outcome	633	641	response
I-outcome	642	646	rate
O	647	650	was
O	651	658	similar
O	659	661	in
O	662	665	the
O	666	668	PC
O	669	672	and
O	673	675	EP
O	676	679	arm
O	680	681	(
B-iv-bin-percent	681	683	89
I-iv-bin-percent	683	684	.
I-iv-bin-percent	684	685	4
I-iv-bin-percent	685	686	%
O	687	689	vs
O	689	690	.
B-cv-bin-percent	691	693	79
I-cv-bin-percent	693	694	.
I-cv-bin-percent	694	695	5
I-cv-bin-percent	695	696	%
O	696	697	,
O	698	699	P
O	700	701	=
O	702	703	0
O	703	704	.
O	704	707	195
O	707	708	)
O	708	709	,
O	710	713	the
B-outcome	714	717	pCR
I-outcome	718	722	rate
O	723	725	in
O	726	729	the
O	730	732	PC
O	733	736	arm
O	737	740	was
O	741	754	significantly
O	755	761	higher
O	762	763	(
B-iv-bin-percent	763	765	38
I-iv-bin-percent	765	766	.
I-iv-bin-percent	766	767	6
I-iv-bin-percent	767	768	%
O	769	771	vs
O	771	772	.
B-cv-bin-percent	773	775	14
I-cv-bin-percent	775	776	.
I-cv-bin-percent	776	777	0
I-cv-bin-percent	777	778	%
O	778	779	,
O	780	781	P
O	782	783	=
O	784	785	0
O	785	786	.
O	786	789	014
O	789	790	)
O	790	791	.

O	792	795	The
O	796	802	median
O	803	809	follow
O	809	810	-
O	810	812	up
O	813	817	time
O	818	821	was
O	822	824	55
O	824	825	.
O	825	826	0
O	827	833	months
O	833	834	.

B-outcome	835	836	5
I-outcome	836	837	-
I-outcome	837	841	year
I-outcome	842	845	RFS
O	846	850	were
B-iv-bin-percent	851	853	77
I-iv-bin-percent	853	854	.
I-iv-bin-percent	854	855	6
I-iv-bin-percent	855	856	%
O	857	860	and
B-cv-bin-percent	861	863	56
I-cv-bin-percent	863	864	.
I-cv-bin-percent	864	865	2
I-cv-bin-percent	865	866	%
O	866	867	,
O	868	881	significantly
O	882	888	higher
O	889	891	in
O	892	895	the
O	896	898	PC
O	899	902	arm
O	902	903	,
O	904	905	P
O	906	907	=
O	908	909	0
O	909	910	.
O	910	913	043
O	913	914	.

O	915	917	No
O	918	929	significant
O	930	940	difference
O	941	943	in
B-outcome	944	946	OS
O	947	950	was
O	951	959	observed
O	960	967	between
O	968	971	the
O	972	975	two
O	976	980	arms
O	981	982	(
O	982	983	P
O	984	985	=
O	986	987	0
O	987	988	.
O	988	991	350
O	991	992	)
O	992	993	.

O	994	1001	Adverse
O	1002	1008	events
O	1009	1013	were
O	1014	1021	similar
O	1021	1022	,
O	1023	1029	except
O	1030	1033	for
O	1034	1038	more
B-outcome	1039	1055	thrombocytopenia
O	1056	1058	in
O	1059	1062	the
O	1063	1065	PC
O	1066	1069	arm
O	1070	1071	(
O	1071	1072	P
O	1073	1074	=
O	1075	1076	0
O	1076	1077	.
O	1077	1080	001
O	1080	1081	)
O	1081	1082	.

B-eligibility	1083	1091	Patients
I-eligibility	1092	1096	with
I-eligibility	1097	1102	stage
I-eligibility	1103	1105	II
I-eligibility	1105	1106	/
I-eligibility	1106	1109	III
I-eligibility	1110	1114	TNBC
O	1115	1119	were
O	1120	1130	randomized
O	1131	1133	to
O	1134	1141	receive
O	1142	1148	either
O	1149	1159	paclitaxel
O	1160	1161	(
O	1161	1164	175
O	1165	1167	mg
O	1167	1168	/
O	1168	1170	m2
O	1170	1171	,
O	1172	1176	day1
O	1176	1177	)
O	1178	1182	plus
O	1183	1194	carboplatin
O	1195	1196	(
O	1196	1200	Area
O	1201	1206	Under
O	1207	1210	the
O	1211	1216	Curve
O	1217	1218	=
O	1219	1220	5
O	1220	1221	,
O	1222	1226	day2
O	1226	1227	)
O	1228	1229	(
O	1229	1231	PC
O	1231	1232	)
O	1233	1235	or
O	1236	1246	epirubicin
O	1247	1248	(
O	1248	1252	75mg
O	1252	1253	/
O	1253	1255	m2
O	1255	1256	,
O	1257	1261	day1
O	1261	1262	)
O	1263	1267	plus
O	1268	1278	paclitaxel
O	1279	1280	(
O	1280	1283	175
O	1284	1286	mg
O	1286	1287	/
O	1287	1289	m2
O	1289	1290	,
O	1291	1295	day2
O	1295	1296	)
O	1297	1298	(
O	1298	1300	EP
O	1300	1301	)
O	1302	1304	as
O	1305	1308	NAC
O	1309	1314	every
O	1315	1320	three
O	1321	1326	weeks
O	1327	1330	for
O	1331	1332	4
O	1332	1333	-
O	1333	1334	6
O	1335	1341	cycles
O	1341	1342	.

O	1343	1346	The
O	1347	1354	primary
O	1355	1363	endpoint
O	1364	1367	was
O	1368	1372	rate
O	1373	1375	of
B-outcome-Measure	1376	1386	pathologic
I-outcome-Measure	1387	1395	complete
I-outcome-Measure	1396	1404	response
I-outcome-Measure	1405	1406	(
I-outcome-Measure	1406	1409	pCR
I-outcome-Measure	1409	1410	)
O	1410	1411	.

O	1412	1415	The
O	1416	1425	secondary
O	1426	1435	endpoints
O	1436	1444	included
B-outcome-Measure	1445	1452	relapse
I-outcome-Measure	1452	1453	-
I-outcome-Measure	1453	1457	free
I-outcome-Measure	1458	1466	survival
I-outcome-Measure	1467	1468	(
I-outcome-Measure	1468	1471	RFS
I-outcome-Measure	1471	1472	)
O	1472	1473	,
B-outcome-Measure	1474	1481	overall
I-outcome-Measure	1482	1490	survival
I-outcome-Measure	1491	1492	(
I-outcome-Measure	1492	1494	OS
I-outcome-Measure	1494	1495	)
O	1496	1499	and
B-outcome-Measure	1500	1506	safety
O	1506	1507	.

O	1508	1512	This
O	1513	1518	study
O	1519	1528	suggested
O	1529	1533	that
O	1534	1537	the
O	1538	1546	addition
O	1547	1549	of
O	1550	1561	carboplatin
O	1562	1564	to
O	1565	1575	paclitaxel
O	1576	1579	was
O	1580	1588	superior
O	1589	1591	to
O	1592	1595	the
O	1596	1603	regimen
O	1604	1606	of
O	1607	1617	epirubicin
O	1618	1622	plus
O	1623	1633	paclitaxel
O	1634	1636	as
O	1637	1640	NAC
O	1641	1644	for
O	1645	1649	TNBC
O	1650	1652	in
O	1653	1658	terms
O	1659	1661	of
O	1662	1671	improving
B-outcome	1672	1675	pCR
I-outcome	1676	1680	rate
I-outcome	1681	1684	and
I-outcome	1685	1688	RFS
O	1688	1689	.

O	1690	1697	Further
O	1698	1703	phase
O	1704	1705	3
O	1706	1711	study
O	1712	1715	has
O	1716	1723	already
O	1724	1731	started
O	1731	1732	.
